Arcline buys PTS from Columbus

Columbus has backed PTS since October 2016, when it led a €1.3m funding round in the company, with participation from several private investors.

Columbus targets early-stage and high-growth opportunities across the life sciences, pharmaceuticals and healthcare industries, investing tickets in the €5-10m range. It focuses on research and development of new therapies, and industrial production of innovative treatments and drugs. The firm has recently held a final close on €120m for its third vehicle, Columbus Life Sciences Fund III.

Arcline intends to boost PTS's growth through the expansion of its production and its technology portfolio, while bringing new technologies to commercial scale.

Arcline is a New York and San Francisco-based private equity firm with $4.3bn in cumulative capital commitments, specialising in investments in mid-market businesses across the defence, aerospace, critical infrastructure services, industrials, medical technology, life sciences and speciality materials sectors. The firm closed its second vehicle, Arcline Capital Partners II, on $2.75bn in February 2021.

Company
Established in 2012 and headquartered in Valencia, PTS manufactures polypeptide-based materials for drug delivery.

The company develops a nanoparticle encapsulation technology for drug delivery applications, including mRNA, DNA, cell therapies, gene therapies, biologics, vaccines, and small-molecule therapies.

PTS's service offering includes pre-clinical development, technology transfer, manufacturing, and fill-and-finish services.

People
Columbus Venture Partners – Damiá Tormo (founding partner).
Polypeptide Therapeutic Solutions – Jose Vicente Pons Andreu (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Exits
• Southern Europe
• Technology
• Venture
• Spain